You are here

  • Home
  • Archive
  • Volume 82, Issue 4
  • Response to: ‘Correspondence on ‘Prevalence and clinical outcomes of COVID-19 in patients with autoimmune diseases: a systematic review and meta-analysis’’ by Lee

Article Text

Article menu
Download PDFPDF
Correspondence response
Response to: ‘Correspondence on ‘Prevalence and clinical outcomes of COVID-19 in patients with autoimmune diseases: a systematic review and meta-analysis’’ by Lee
  1. Shintaro Akiyama1,
  2. Shadi Hamdeh2,
  3. Dejan Micic1,
  4. Atsushi Sakuraba1
  1. 1 Inflammatory Bowel Disease Center, The University of Chicago Medicine, Chicago, Illinois, USA
  2. 2 Department of Internal Medicine, Division of Gastroenterology, Hepatology and Motility, University of Kansas, Kansas City, Kansas, USA
  1. Correspondence to Dr Atsushi Sakuraba, Inflammatory Bowel Disease Center, The University of Chicago Medicine, Chicago, Illinois, USA; asakurab{at}medicine.bsd.uchicago.edu

http://dx.doi.org/10.1136/annrheumdis-2021-219918

Statistics from Altmetric.com

    Request Permissions

    If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

    We thank Lee1 for his comments to our research article ‘Prevalence and clinical outcomes of COVID-19 in patients with autoimmune diseases: a systematic review and meta-analysis’.2

    In our study, included patients were likely on glucocorticoids (GCs) for their underlying autoimmune diseases (ADs), not for COVID-19-associated pneumonia and cytokine release syndrome. Hence, our data suggested the possibility of harmful effects of chronic use of GCs on the risk of developing SARS-CoV-2 infection and severe COVID-19. We were unable to analyse the therapeutic effect of GCs in patients with ADs who developed COVID-19 pneumonia. As stated in the correspondence by Lee,1 a systematic review and …

    View Full Text

    Footnotes

    • Handling editor Josef S Smolen

    • Contributors Drafting of manuscript: SA, SH, DM and AS. Critical review of manuscript: SA and AS.

    • Funding The authors have not declared a specific grant for this research from any funding agency in the public, commercial or not-for-profit sectors.

    • Competing interests None declared.

    • Patient and public involvement Patients and/or the public were not involved in the design, or conduct, or reporting, or dissemination plans of this research.

    • Provenance and peer review Commissioned; internally peer reviewed.

    Linked Articles